Q-omics provides the consensus-scored MAP4K1 profile across patient tissues and cancer cell-line models. MAP4K1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MAP4K1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MAP4K1 protein abundance shows 31,897 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where MAP4K1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP4K1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP4K1 survival associations across molecular data types. MAP4K1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP4K1 RNA expression–survival associations across cancer types. High MAP4K1 expression shows unfavorable associations in LGG, but favorable associations in HNSC, CESC, BLCA, LUAD and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MAP4K1 RNA expression.
This table summarizes MAP4K1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAP4K1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP4K1 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, KIRP, STAD and BRCA. The KIRC box plot shows higher MAP4K1 RNA expression in tumor versus normal tissue (log2 FC = +1.731, t-test p < 0.001).
This table shows molecular features associated with MAP4K1 in patient tissues and cancer cell lines. In patient samples, MAP4K1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP4K1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
